A 28-year-old man with a history of unprovoked deep vein thrombosis presents with acute myocardial infarction. He is found to have antithrombin III deficiency. Which anticoagulant is the drug of choice for acute VTE management in this patient given his thrombophilic state?

Explanation

## Antithrombin III Deficiency and Acute VTE Management **Key Point:** Antithrombin III (AT-III) deficiency is a rare inherited thrombophilia characterized by reduced levels of antithrombin, a natural anticoagulant that inhibits thrombin and Factor Xa. Patients with AT-III deficiency have a markedly increased risk of VTE and require careful anticoagulation. ### Anticoagulation Strategy in AT-III Deficiency **High-Yield:** Unfractionated heparin (UFH) is the drug of choice for acute VTE in patients with AT-III deficiency because: 1. Heparin works via antithrombin; however, UFH has direct anti-Xa and anti-IIa activity independent of antithrombin at high concentrations. 2. UFH allows for rapid reversal with protamine sulfate if bleeding occurs. 3. UFH can be monitored with activated partial thromboplastin time (aPTT) and adjusted in real-time. 4. Low-molecular-weight heparin (LMWH) is relatively contraindicated in AT-III deficiency because it depends more heavily on antithrombin for its anticoagulant effect. | Drug | Mechanism | AT-III Dependence | Use in AT-III Deficiency | |------|-----------|-------------------|-------------------------| | **Unfractionated Heparin** | Potentiates antithrombin; direct anti-Xa/IIa at high doses | Partial (has intrinsic activity) | **Preferred** | | LMWH | Potentiates antithrombin (primarily anti-Xa) | High | Relatively contraindicated | | Warfarin | Inhibits vitamin K-dependent factors | None | Bridging agent after UFH | | Rivaroxaban | Direct Factor Xa inhibitor | None | Not first-line for acute VTE | | Aspirin | Antiplatelet | None | Ineffective for VTE | ### Clinical Pearl **Clinical Pearl:** Patients with AT-III deficiency may require higher doses of heparin and may be "heparin-resistant" (requiring >35,000 units/day). Fresh frozen plasma (FFP) or antithrombin concentrate may be administered to raise AT-III levels and improve heparin responsiveness. **Mnemonic — Heparin in AT-III Deficiency: UFH-SAFE** - **U**nfractionated heparin (preferred) - **F**ast reversal (protamine) - **H**igh-dose requirement (heparin resistance) - **S**afe monitoring (aPTT) - **A**ntithrombin concentrate (adjunctive) - **F**resh frozen plasma (adjunctive) - **E**scape route (rapid reversal if needed) **Warning:** LMWH should be avoided in AT-III deficiency because it depends almost entirely on antithrombin for anticoagulation; patients may not achieve therapeutic anticoagulation. Warfarin monotherapy is inadequate for acute VTE and requires heparin bridging.